Full text is available at the source.
Abstract
Research on psychedelic therapies in children and adolescents is currently absent despite growing interest in their use for mental health treatment.
- Psychedelic substances like 3,4-methylenedioxymethamphetamine, psilocybin, and lysergic acid diethylamide show promise for treating various mental health disorders in adults.
- There are no recent clinical trials investigating these therapies in children and adolescents.
- Adolescents may be experimenting with psychedelic substances for recreational and therapeutic reasons due to increased accessibility.
- This situation raises significant concerns regarding the safety and well-being of adolescents, who are considered a vulnerable population.
- There is a call for structured and controlled studies to explore the potential of psychedelic therapies in this age group.
Simplified